Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Telesis Bio Inc (TBIO)

Telesis Bio Inc (TBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,493
  • Shares Outstanding, K 29,984
  • Annual Sales, $ 27,440 K
  • Annual Income, $ -48,470 K
  • 60-Month Beta 1.98
  • Price/Sales 0.45
  • Price/Cash Flow N/A
  • Price/Book 0.76
Trade TBIO with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.30
  • Most Recent Earnings $-0.37 on 11/13/23
  • Latest Earnings Date 04/02/24 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 200.50%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.25
  • Number of Estimates 2
  • High Estimate -0.16
  • Low Estimate -0.33
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +10.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3601 +22.88%
on 03/20/24
0.5899 -24.99%
on 03/12/24
-0.1174 (-20.97%)
since 02/28/24
3-Month
0.3010 +47.01%
on 01/18/24
0.8590 -48.49%
on 02/23/24
+0.0425 (+10.62%)
since 12/28/23
52-Week
0.3000 +47.50%
on 11/21/23
3.3199 -86.67%
on 03/31/23
-2.3175 (-83.97%)
since 03/28/23

Most Recent Stories

More News
Emergent Biosolutions (EBS) Reports Q1 Loss, Tops Revenue Estimates

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -89.82% and 15.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

EBS : 2.59 (-0.77%)
TBIO : 0.4449 (-1.13%)
Beat the Market the Zacks Way: Hershey's, Telesis Bio, General Mills in Focus

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

HSY : 195.60 (+0.98%)
GIS : 70.32 (+0.95%)
TSCO : 261.55 (+0.43%)
AZO : 3,162.89 (-0.94%)
YPF : 19.87 (-1.24%)
TBIO : 0.4449 (-1.13%)
BDORY : 11.2550 (+1.03%)
AXON : 313.26 (-0.75%)
NOBL : 101.28 (+0.21%)
PD : 22.42 (+2.00%)
GEHC : 90.72 (+0.45%)
Telesis Bio (TBIO) Reports Q4 Loss, Tops Revenue Estimates

Telesis Bio (TBIO) delivered earnings and revenue surprises of 12.50% and 5.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

TBIO : 0.4449 (-1.13%)
RETA : 172.36 (+0.02%)
Paratek Pharmaceuticals (PRTK) Reports Q4 Loss, Tops Revenue Estimates

Paratek (PRTK) delivered earnings and revenue surprises of -1,300% and 33.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

PRTK : 2.23 (+1.83%)
TBIO : 0.4449 (-1.13%)
Should You Buy Telesis Bio (TBIO) After Golden Cross?

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

TBIO : 0.4449 (-1.13%)
Evogene (EVGN) Reports Q4 Loss, Tops Revenue Estimates

Evogene (EVGN) delivered earnings and revenue surprises of 66.67% and 20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

EVGN : 0.7500 (+2.01%)
TBIO : 0.4449 (-1.13%)
Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Tops Revenue Estimates

Acadia (ACAD) delivered earnings and revenue surprises of -4% and 1.55%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ACAD : 18.32 (+0.66%)
TBIO : 0.4449 (-1.13%)
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

LEXINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines...

TBIO : 0.4449 (-1.13%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates TGRF, SIC, SAFM, TBIO; Shareholders are Encouraged to Contact the Firm

NEW YORK, NY / ACCESSWIRE / August 26, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: TGR Financial, Inc. (OTCQX:TGRF) concerning potential...

TGRF : 15.5500 (+1.83%)
SIC : 14.49 (+0.07%)
SAFM : 204.00 (-2.51%)
TBIO : 0.4449 (-1.13%)
INVESTIGATION: Halper Sadeh LLP Investigates CMO, TBIO, SIC, SAFM; Shareholders are Encouraged to Contact the Firm

NEW YORK, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

CMO : 6.50 (+2.52%)
TBIO : 0.4449 (-1.13%)
SIC : 14.49 (+0.07%)
SAFM : 204.00 (-2.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Telesis Bio is an automated multi-omic and synthetic biology solutions company. Its BioXp(R) system consolidates, automates and optimizes the entire synthesis, cloning and amplification workflow. Telesis Bio, formerly known as Codex DNA Inc., is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 0.4791
2nd Resistance Point 0.4645
1st Resistance Point 0.4573
Last Price 0.4449
1st Support Level 0.4355
2nd Support Level 0.4209
3rd Support Level 0.4137

See More

52-Week High 3.3199
Fibonacci 61.8% 2.1663
Fibonacci 50% 1.8099
Fibonacci 38.2% 1.4536
Last Price 0.4449
52-Week Low 0.3000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar